An exodus of top Gilead execs continues as newly named CMO Andrew Cheng heads for the exit
The exodus of top execs out of a high-performing Gilead is continuing Tuesday evening.
The biotech, which has been the most productive drug developer over the past 5 years, noted Tuesday night that Chief Medical Officer Andrew Cheng is leaving the company “to pursue another opportunity.”
As of now, we don’t know what that other opportunity is, but Gilead $GILD has recently seen the departure of chief R&D exec Norbert Bischofberger (to a startup) as well as the announced exits of CEO John Milligan and longtime company exec John Martin, executive chairman.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.